Next-Generation Synthetic and Biocatalytic Strategies for Therapeutic Oligonucleotide Production: A Process Chemistry Perspective

Abstract The rapid expansion of oligonucleotide therapeutics has created unprecedented demand for robust, scalable, and economically sustainable manufacturing technologies. While solid-phase phosphoramidite synthesis remains the industry standard for manufacturing antisense oligonucleotides, siRNAs, guide RNAs, aptamers, and other modified oligonucleotides, increasing sequence complexity, extensive chemical modifications, ligand conjugation, sustainability concerns, and manufacturing costs continue to challenge conventional production processes. This review provides a comprehensive process chemistry perspective on next-generation oligonucleotide manufacturing by integrating advances across chemical synthesis, raw material supply, bioconjugation, and emerging biocatalytic technologies. We first review the evolution of phosphoramidite chemistry, including the industrial manufacture of nucleoside phosphoramidites, controlled pore glass and polystyrene supports, synthesis reagents, and modified nucleotide building blocks that underpin commercial oligonucleotide production. The discussion then highlights downstream process development, purification strategies, and manufacturing considerations associated with large-scale oligonucleotide production, followed by recent advances in site-specific bioconjugation with ligands including GalNAc, lipids, peptides, and antibodies that have significantly expanded the extrahepatic delivery of therapeutic oligonucleotide drugs. We emphasize on emerging enzymatic and chemoenzymatic manufacturing platforms, including early ligase-mediated fragment assembly, template-independent terminal deoxynucleotidyl transferase-based controlled enzymatic synthesis, the industrial translation represented by Codexis ECO Synthesis, and the EnPlusOne ezRNA protocols. Finally, we discuss the need for expanding supply chain for modified nucleoside triphosphates, engineered polymerases, ligases, and accessory enzymes. Collectively, these advances demonstrate how the convergence of synthetic chemistry, enzyme engineering, and industrial bioprocess development is reshaping oligonucleotide manufacturing and establishing the foundation for next-generation, cost-effective, and environmentally sustainable production of increasingly complex nucleic acid therapeutics.

Authors

Institutions

Publication Details

Journal
Organic Process Research & Development
Published
2026-11-13
DOI
https://doi.org/10.1021/acs.oprd.6c00397
Primary Topic
DNA and Nucleic Acid Chemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Next-Generation Synthetic and Biocatalytic Strategies for Therapeutic Oligonucleotide Production: A Process Chemistry Perspective

Anilkumar R. Kore, Yogesh S. Sanghvi, Dnyaneshwar Rasale
3 links
Organic Process Research & Development
DNA and Nucleic Acid Chemistry
article

Next-Generation Synthetic and Biocatalytic Strategies for Therapeutic Oligonucleotide Production: A Process Chemistry Perspective

Anilkumar R. Kore, Yogesh S. Sanghvi, Dnyaneshwar Rasale
article en

Abstract

Abstract The rapid expansion of oligonucleotide therapeutics has created unprecedented demand for robust, scalable, and economically sustainable manufacturing technologies. While solid-phase phosphoramidite synthesis remains the industry standard for manufacturing antisense oligonucleotides, siRNAs, guide RNAs, aptamers, and other modified oligonucleotides, increasing sequence complexity, extensive chemical modifications, ligand conjugation, sustainability concerns, and manufacturing costs continue to challenge conventional production processes. This review provides a comprehensive process chemistry perspective on next-generation oligonucleotide manufacturing by integrating advances across chemical synthesis, raw material supply, bioconjugation, and emerging biocatalytic technologies. We first review the evolution of phosphoramidite chemistry, including the industrial manufacture of nucleoside phosphoramidites, controlled pore glass and polystyrene supports, synthesis reagents, and modified nucleotide building blocks that underpin commercial oligonucleotide production. The discussion then highlights downstream process development, purification strategies, and manufacturing considerations associated with large-scale oligonucleotide production, followed by recent advances in site-specific bioconjugation with ligands including GalNAc, lipids, peptides, and antibodies that have significantly expanded the extrahepatic delivery of therapeutic oligonucleotide drugs. We emphasize on emerging enzymatic and chemoenzymatic manufacturing platforms, including early ligase-mediated fragment assembly, template-independent terminal deoxynucleotidyl transferase-based controlled enzymatic synthesis, the industrial translation represented by Codexis ECO Synthesis, and the EnPlusOne ezRNA protocols. Finally, we discuss the need for expanding supply chain for modified nucleoside triphosphates, engineered polymerases, ligases, and accessory enzymes. Collectively, these advances demonstrate how the convergence of synthetic chemistry, enzyme engineering, and industrial bioprocess development is reshaping oligonucleotide manufacturing and establishing the foundation for next-generation, cost-effective, and environmentally sustainable production of increasingly complex nucleic acid therapeutics.

Organic Process Research & Development
EMD Serono, Inc. (United States) (US), Merck Healthcare KGaA, Darmstadt (Germany) (DE)
DNA and Nucleic Acid Chemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon